AstraZeneca has already provided the requested information to the FDA and a decision on the updated BLA is expected in the first half of 2026.

Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 ...

The collaboration between ten23 health and BD aims to commercialize the BD Libertas wearable injector for large-volume ...

The FDA is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab).

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

Investing.com -- AstraZeneca PLC (ST:AZN) stock fell 1.5% in Tuesday morning trade after the U.S. Food and Drug Administration rejected the company’s initial submission for its Saphnelo lupus drug in ...

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...